Related Experiment Videos
Imipenem/cilastatin in the treatment of osteomyelitis
Abstract:
Thirty-four patients with osteomyelitis were treated for a mean of 32.5 days with 2 to 4 g per day of imipenem/cilastatin. Twenty-six infections involving the lower extremities were associated with accidents and prosthesis implantation, and 19 of 34 patients had more than one organism isolated. Gram-positive and gram-negative organisms were equally represented, but follow-up bone culture samples showed only 11 percent of gram-positive organisms persisted versus 23 percent of gram-negative organisms. Seventy-four percent of patients were cured or improved, and failures were related to resistant organisms and the inability to perform adequate surgical debridement. Adverse drug side effects included nausea, diarrhea, liver enzyme elevations, and neutropenia, but discontinuation of treatment was required in only three patients. Imipenem/cilastatin holds promise as monotherapy in complicated polymicrobial osteomyelitis.
Insights
Imipenem/cilastatin effectively treated complicated osteomyelitis in 74% of patients. This antibiotic combination shows promise for polymicrobial bone infections, with few adverse effects.
Area of Science:
- Infectious Diseases
- Orthopedic Surgery
- Pharmacology
Background:
- Osteomyelitis is a serious bone infection often caused by multiple microorganisms.
- Lower extremity infections, frequently linked to trauma and implants, pose treatment challenges.
Purpose of the Study:
- To evaluate the efficacy and safety of imipenem/cilastatin as monotherapy for complicated osteomyelitis.
- To assess treatment outcomes in patients with polymicrobial bone infections.
Main Methods:
- A study involving 34 patients with osteomyelitis treated with imipenem/cilastatin (2-4 g/day) for a mean of 32.5 days.
- Inclusion of patients with lower extremity infections, often associated with accidents or prosthesis implantation.
- Microbiological analysis of initial and follow-up bone cultures to track organism persistence.
Main Results:
- 74% of patients achieved cure or improvement.
- Gram-negative organisms showed higher persistence rates (23%) compared to Gram-positive (11%) in follow-up cultures.
- Treatment failures were associated with resistant organisms and inadequate surgical debridement.
- Adverse events (nausea, diarrhea, elevated liver enzymes, neutropenia) were generally mild, requiring discontinuation in only 3 patients.
Conclusions:
- Imipenem/cilastatin demonstrates significant promise as a monotherapy option for complicated polymicrobial osteomyelitis.
- Effective management requires addressing resistant organisms and ensuring adequate surgical intervention.
- The safety profile of imipenem/cilastatin in this patient group is favorable.